Search Results - "Le Meur, Y"

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing by Thervet, E, Loriot, M A, Barbier, S, Buchler, M, Ficheux, M, Choukroun, G, Toupance, O, Touchard, G, Alberti, C, Le Pogamp, P, Moulin, B, Le Meur, Y, Heng, A E, Subra, J F, Beaune, P, Legendre, C

“…Retrospective studies have demonstrated that patients who are expressors of cytochrome P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a…”
Get full text

Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study by Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Durrbach, A., Albano, L., Rivalan, J., Le Meur, Y., Essig, M., Bouvier, N., Legendre, C., Moulin, B., Heng, A.‐E., Weestel, P.‐F., Sayegh, J., Charpentier, B., Rostaing, L., Thervet, E., Lebranchu, Y.

“…The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended‐release tacrolimus (TacER)…”
Get full text

Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor–Intolerant Graft Recipients of Kidneys From Extended‐Criteria Donors by Le Meur, Y., Aulagnon, F., Bertrand, D., Heng, A. E., Lavaud, S., Caillard, S., Longuet, H., Sberro‐Soussan, R., Doucet, L., Grall, A., Legendre, C.

“…Transplant recipients receiving a kidney from an extended‐criteria donor (ECD) are exposed to calcineurin inhibitor (CNI) nephrotoxicity, as demonstrated by…”
Get full text

Long‐Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype by Pallet, N., Etienne, I., Buchler, M., Bailly, E., Hurault de Ligny, B., Choukroun, G., Colosio, C., Thierry, A., Vigneau, C., Moulin, B., Le Meur, Y., Heng, A.‐E., Legendre, C., Beaune, P., Loriot, M. A., Thervet, E.

“…Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is associated with improved achievement of target trough concentration (C0),…”
Get full text

Elite synchronized swimmers display decreased energy availability during intensified training by Schaal, K., Tiollier, E., Le Meur, Y., Casazza, G., Hausswirth, C.

“…Elite synchronized swimmers follow high‐volume training regimen that result in elevated rates of exercise energy expenditure (ExEE). While adequate energy…”
Get full text

Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation by Le Meur, Y., Büchler, M., Thierry, A., Caillard, S., Villemain, F., Lavaud, S., Etienne, I., Westeel, P.‐F., De Ligny, B. H., Rostaing, L., Thervet, E., Szelag, J. C., Rérolle, J.‐P., Rousseau, A., Touchard, G., Marquet, P.

“…Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite,…”
Get full text

Effects of a 6-Week Period of Polarized or Threshold Training on Performance and Fatigue in Elite Swimmers by Pla, R, Le Meur, Y, Aubry, A, Toussaint, J F, Hellard, P

“…To quantify the impact of a polarized distribution of training intensity on performance and fatigue in elite swimmers. Twenty-two elite junior swimmers (12…”
Get more information

Heat‐acclimatization and pre‐cooling: a further boost for endurance performance? by Schmit, C., Le Meur, Y., Duffield, R., Robach, P., Oussedik, N., Coutts, A. J., Hausswirth, C.

“…To determine if pre‐cooling (PC) following heat‐acclimatization (HA) can further improve self‐paced endurance performance in the heat, 13 male triathletes…”
Get full text

Kidney Transplant Recipients Carrying the CYP3A422 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations by Pallet, N., Jannot, A.‐S., El Bahri, M., Etienne, I., Buchler, M., de Ligny, B. H., Choukroun, G., Colosio, C., Thierry, A., Vigneau, C., Moulin, B., Le Meur, Y., Heng, A.‐E., Subra, J.‐F., Legendre, C., Beaune, P., Alberti, C., Loriot, M. A., Thervet, E.

“…CYP3A4*22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased activity. Carriers of this polymorphism may require reduced tacrolimus…”
Get full text

Exposure to Mycophenolic Acid Better Predicts Immunosuppressive Efficacy Than Exposure to Calcineurin Inhibitors in Renal Transplant Patients by Daher Abdi, Z, Prémaud, A, Essig, M, Alain, S, Munteanu, E, Garnier, F, Le Meur, Y, Marquet, P, Rousseau, A

“…A time–to–event model was developed to study the predictive factors of immunosuppressive efficacy in renal transplant patients and to investigate longitudinal…”
Get full text

Genome‐Wide Association Study of Acute Renal Graft Rejection by Ghisdal, L., Baron, C., Lebranchu, Y., Viklický, O., Konarikova, A., Naesens, M., Kuypers, D., Dinic, M., Alamartine, E., Touchard, G., Antoine, T., Essig, M., Rerolle, J. P., Merville, P., Taupin, J. L., Le Meur, Y., Grall‐Jezequel, A., Glowacki, F., Noël, C., Legendre, C., Anglicheau, D., Broeders, N., Coppieters, W., Docampo, E., Georges, M., Ajarchouh, Z., Massart, A., Racapé, J., Abramowicz, D., Abramowicz, M.

“…Acute renal rejection is a major risk factor for chronic allograft dysfunction and long‐term graft loss. We performed a genome‐wide association study to detect…”
Get full text

Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up by Woillard, J‐B, Rerolle, J‐P, Picard, N, Rousseau, A, Guillaudeau, A, Munteanu, E, Essig, M, Drouet, M, Le Meur, Y, Marquet, P

“…Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P‐glycoprotein (P‐gp; ABCB1), both abundantly expressed in the kidney. In…”
Get full text

High Dose Epoetin Beta in the First Weeks Following Renal Transplantation and Delayed Graft Function: Results of the Neo‐PDGF Study by Martinez, F., Kamar, N., Pallet, N., Lang, P., Durrbach, A., Lebranchu, Y., Adem, A., Barbier, S., Cassuto‐Viguier, E., Glowaki, F., Le Meur, Y., Rostaing, L., Legendre, C., Hermine, O., Choukroun, G.

“…Erythropoietin promotes nephroprotection in animal models of ischemia‐reperfusion injury. Neorecormon® and Prevention of Delayed Graft Function (Neo‐PDGF) is a…”
Get full text

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study by Gaiffe, E, Crepin, T, Bamoulid, J, Courivaud, C, Büchler, M, Cassuto, E, Albano, L, Chemouny, J M, Choukroun, G, Hazzan, M, Kessler, L, Legendre, C, Le Meur, Y, Ouali, N, Thierry, A, Anota, A, Nerich, V, Limat, S, Bonnetain, F, Vernerey, D, Ducloux, D

“…Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease…”
Get full text

Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach by Daher Abdi, Z., Essig, M., Rizopoulos, D., Le Meur, Y., Prémaud, A., Woillard, J.B., Rérolle, J.P., Marquet, P., Rousseau, A.

“…This study aimed to investigate the association between longitudinal exposure to mycophenolic acid (MPA) and acute rejection (AR) risk in the first year after…”
Get full text

Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study by Legendre, Christophe, Merville, Pierre, Heng, A.-E., Moulin, B., Queré, S., Di Giambattista, F., Lecuyer, A., Touchard, G., Le Meur, Yannick, Villemain, F., Kamar, Nassim, Toupance, O., Choukroun, G., Büchler, M., Mourad, Georges, Thierry, A., Kessler, M.

“…In a six-month, multicenter, open-label trial, de novo kidney transplant recipients at low immunological risk were randomized to steroid avoidance or steroid…”
Get full text

A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry by Benkali, K, Marquet, P, Rérolle, Jp, Le Meur, Y, Gastinel, Ln

“…LC-MALDI-TOF/TOF analysis is a potent tool in biomarkers discovery characterized by its high sensitivity and high throughput capacity. However, methods based…”
Get full text

B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner by Nouël, A, Pochard, P, Simon, Q, Ségalen, I, Le Meur, Y, Pers, J.O, Hillion, S

“…Abstract A number of studies have suggested that B cell mediated-regulation contributes to the establishment of immunological tolerance. However, the precise…”
Get full text

Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients by Prémaud, A., Rousseau, A., Le Meur, Y., Venisse, N., Loichot, C., Turcant, A., Hoizey, G., Compagnon, P., Hary, L., Debruyne, D., Saivin, S., Jacqz-Aigrain, E., Marquet, P.

“…The aim of this study was to analyze retrospectively and critically the different steps of the individual dose adjustment procedure employed in the…”
Get full text

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study by Lebranchu, Y., Thierry, A., Toupance, O., Westeel, P. F., Etienne, I., Thervet, E., Moulin, B., Frouget, T., Le Meur, Y., Glotz, D., Heng, A‐E., Onno, C., Buchler, M., Girardot‐Seguin, S., De Ligny, B. Hurault

“…Sirolimus (SRL) allows to minimize the use of cyclosporine (CsA), but de novo administration after transplantation is associated with various complications. We…”
Get full text